By Reuters | September 6th, 2013

Expanding the investigation to include the China allegations is a routine step.

By Wall Street Journal | September 6th, 2013

U.K. laws could prevent it from pursuing a case against one of its own companies if Chinese and U.S. authorities have gotten there first.

By Bloomberg | August 28th, 2013

A probe of JPMorgan Chase & Co.’s hiring practices in China has uncovered red flags across Asia, including an internal spreadsheet that linked appointments to specific deals pursued by the bank, people with knowledge of the matter said.

By Reuters | August 22nd, 2013

U.S. drugmaker Eli Lilly and Co said it was “deeply concerned” about allegations published in a Chinese newspaper that it spent more than 30 million yuan ($4.90 million) to bribe doctors in China to prescribe the firm’s medicines instead of rival products.

By Douglas Gillison | August 16th, 2013

The U.S. has taken the lead on investigating the mining concern, with Australian authorities embarrassed into taking belated action.

By Katy O'Donnell | August 14th, 2013

Chinese authorities have recently brought intense pressure to bear on foreign drug makers over alleged bribery.

By Douglas Gillison | August 9th, 2013

Company directors won plaudits for the acquisition of a Chinese drug maker in 2011 but the outcome has been less rosy than it may originally have seemed.

By Katy O'Donnell | August 2nd, 2013

At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca.

By Douglas Gillison | August 1st, 2013

A low-ball initial offer is rejected and Avon says it expects to pay more for alleged bribes in China and other countries. (Subscription required)

By Main Justice staff | July 29th, 2013

Just Anti-Corruption reported the disclosure as it occurred last year. Other media suggested the disclosure was made this week.

By Katy O'Donnell | July 26th, 2013

The judge refused to approve the deal for two years without the company agreeing to file reports to both him and the SEC on any potential violation.

By Katy O'Donnell | July 17th, 2013

If GSK isn’t the only pharmaceutical company under investigation by Chinese authorities, a look to the list of drug makers whose conduct in China has also been probed by the United States may offer clues to the others.

By Katy O'Donnell | July 16th, 2013

Chinese authorities have detained four GSK executives on bribery allegations in a notably aggressive crackdown on the British pharmaceutical company.

By Wall Street Journal | July 8th, 2013

U.K. drug maker GlaxoSmithKline PLC is investigating allegations that sales personnel in China rewarded doctors with cash and perks for prescribing Botox, and allegedly tried to cover their tracks by using private email, as part of a broader probe into allegations of bribery that date back several years.

By Associated Press | June 13th, 2013

Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing.

Ernst & Young LLP
Dealing with complex issues of fraud, regulatory compliance and business disputes can detract from efforts to succ... more
Covington & Burling LLP
ANALYSIS: The UK Government’s New Anti-Corruption Plan more
Morrison & Foerster LLP
ANALYSIS: Top Ten International Anti-Corruption Developments for December 2014 more
Shearman & Sterling LLP
ANALYSIS: Recent Trends and Patterns in the Enforcement of the Foreign Corrupt Practices Act more
McGuireWoods LLP
ANALYSIS: DOJ, SEC Inquiry into Och-Ziff Capital “Placement Fee” Payment Highlights Continuing FCPA Scrutiny more
A&L Goodbody
ANALYSIS: Preparing Your Business for Ireland's Impending Anti-Bribery Laws  more
Taft Stettinius & Hollister LLP
ANALYSIS: Chinese President and SEC/DOJ Send the Same Message - Reinforce Your Chinese Anti-Corruption Compli... more

President Obama announces Loretta Lynch as nominee for Attorney General.

An error has occurred, which probably means the feed is down. Try again later.